Skip to main content
. 2020 Feb 28;11:183. doi: 10.3389/fphar.2020.00183

Figure 1.

Figure 1

Experimental designs and the effect of chronic treatment with ligands of mGlu2/3 receptors on locomotor functions in acute or sub-acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s disease (PD) mice models. (A) Molecular formula of LY354740. (B) Molecular formula of LY341495. (C) Schematic representation of the sub-acute MPTP-induced PD mice model experimental scheme. (D) Experimental design of acute-MPTP induced PD mice models. Representative analysis of rotarod tests (E) and pole tests (G) in sub-acute MPTP mice models. Behavioral tests were performed 30 min after the last treatment of drug intervention in sub-acute MPTP mice models on the fourteenth day. #p < 0.05, ##p < 0.01 compared with the MPTP + saline group; &p < 0.05, &&p < 0.01 compared with MPTP + LY341495 group. N = 8. Error bars represent SEM. Analysis of rotarod tests (F) and pole tests (H) on the seventh day of the experiment in acute MPTP mice models. Behavioral tests were performed 30 min after the last treatment of drug intervention. #p < 0.05, ##p < 0.01 compared with the MPTP + saline group; &p < 0.05, &&p < 0.01 compared with the MPTP + LY341495 group. N = 8. Error bars represent SEM.